Are you optimizing
clinical intelligence?

The right data and strategic insights are often elusive. That is why MDCPartners takes deeper dives for our clients in the pharmaceutical and medical industries. By merging our business expertise with unique IT platforms and portals we can fully support your intelligence and business needs for clinical trial optimization, medical expert identification, and regulatory compliance.

Strategic data advances clinical development

MDCPartners is dedicated to providing tools and services to help pharmaceutical companies make better decisions. Our flagship product, ta-Scan, is a web-based data platform that helps users monitor, aggregate, and analyze regulatory data, trial data, and expert profiles. Whether you need to optimize study placement, select research partners, or manage your portfolios, our products and portals will help you bridge the information gaps in today’s competitive clinical research environment.

Learn more about ta-Scan 5

Are your medical devices meeting standards?

To support manufacturers of medical devices and in vitro diagnostics (IVDs), MDCPartners has developed normScan, a web-based standards tracking tool tailored to your product range. It can also help you obtain regulatory approval for marketing products throughout Europe, and can assist you with a broad spectrum of regulatory issues related to maintaining compliance.

Learn more about normScan

Bring your own data, use our know-how

MDCPartners doesn’t just offer tools for visualizing public data. We also provide tools for depicting external client data merged with information from our public data cloud. So if you have specific needs that surpass the scope of ta-Scan, you can still rely on us for tailor-made real world data solutions.

Learn more about our data solutions

Latest News & Events

Find medical experts on the go with Podium

With ta-Scan Podium, our new semantic search application, MDCPartners is going mobile. Podium allows you to leverage the powerful search capabilities of ta-Scan’s clinical intelligence database to find Key External Experts on the go, using any tablet device.

If you are moving into a new disease area or if you are trying to identify new therapeutic experts in an existing indication, why remain limited to the endless number of databases, only available on your desktop? Whether you’re at your desk, at a meeting or a conference, you can now search, refine, save, and share any expert profile with a few simple clicks on your tablet.

Learn more about Podium in the video below and see how it can improve your work effectiveness.
Book your free demo using the following link →

Share on:
Tweet about this on TwitterShare on LinkedIn
ESMO 2017 abstracts ta-Scan

ESMO 2017 Highlights by ta-Scan

ESMO 2017 abstracts ta-Scan

ESMO at a glance

With almost 24,000 professionals visiting Madrid, attendance at ESMO 2017 was almost 20% higher than we had anticipated. The number of abstracts clocked in at 1736, of which 541 discussed clinical trials. Commercial companies were well represented among the earlier abstracts, so no significant change occurred in the number of companies. We did see a big increase in the number of abstracts from the top commercial sponsors.

ESMO 2017 abstracts ta-Scan basic data

TA distribution

In our preliminary analysis we drew attention to the large abstract volume for breast cancer with 25% of all available abstracts mentioning this TA. Now that the late-breaking abstracts are in, breast cancer dropped to about 20%. This is mainly due to a large increase in abstracts about gastrointestinal cancers. Especially colorectal cancer and stomach cancer were popular topics in the late-breaking abstracts. All in all, the abstract volumes per indication now match those of 2016 much more closely, as you can see in the next graph.

ESMO 2017 abstracts ta-Scan ta distribution tree map

TA distribution over time

We can now compare the full abstract volumes of 2017 with those of 2016 to find the top rising and top declining indications. The overall abstract volume has increased, so rather than compare raw numbers, we will look at each year’s relative abstract volumes and compare those to estimate how much more or less popular certain indications are.

Abstract volumes have not deviated a lot from 2016 and with a mere 2% increase in relative abstract volume, stomach cancer tops the list of indications with the biggest increase in interest.

In our prior analysis, colorectal cancer was our biggest declining indication, and despite almost doubling its abstract count with late-breaking abstracts, it still makes it into the top 3 declining indications compared to 2016. The drop in lung cancer comes as something of a surprise, considering the excellent presentations on that topic.

ESMO 2017 abstracts ta-Scan ta distribution over time column chart

Top sponsors at a glance

The immune-oncology players presented new successes alone and in combination with other drugs this year. Merck & Co. sees its pembrolizumab perform well in several combinations, among which the combination with IDO inhibitor epacadostat from Incyte displayed notably consistent results. Bristol-Myers Squibb continues to push its combination of nivolumab and ipilimumab forward and presented good results in kidney cancer, while AstraZeneca impressed attendees of the first presidential symposium with good data on both durvalumab and osimertinib in lung cancer.

During the third presidential symposium we saw the results of 2 competing BRAF inhibitors in stage 3 melanoma with a clear win going to Novartis‘s combination of dabrafenib + trametinib, while Roche-Genentech‘s trial on vemurafenib did not meet its primary endpoint. It would seem that the addition of the MEK inhibitor really adds to the therapy’s efficacy, an idea not missed by other competitors such as Array Biopharma. The latter company also presented encouraging data at ESMO on its BRAF + MEK inhibitor combination encorafenib + binimetinib, for which the first NDA was accepted the day after ESMO ended.

Lastly, Pfizer and Novartis are turning to combination therapies in the CDK4/6 inhibitor space with palbociclib and ribociclib respectively, whereas competitor Eli Lilly presented good, but not differentiating results on their CDK4/6 inhibitor abemaciclib.

ESMO 2017 abstracts ta-Scan top sponsors

Summary of recent developments

ESMO 2017 delivered! Cancer research is booming and the numbers reflect that, as the annual ESMO conferences continue to grow in size each year. Attendees have gained new insights, learned about the latest research efforts, and witnessed the successes and failures of compounds in several large clinical studies.

The late-breaking abstracts revealed a lot more data on compounds being tested in the clinic. The continued success of immune checkpoint inhibitors and several targeted approaches are encouraging. New targets attract a lot of attention, but we were equally impressed with the progress made on well-known targets such as EGFR.

With another successful edition of the annual ESMO conferences behind us, we now are looking forward to the SCOPE Summit in February. Register now to meet the ta-Scan team there at booth #300.

ta-Scan SCOPE 2018
Share on:
Tweet about this on TwitterShare on LinkedIn
Immuno-Oncology Summit 2017 ta-Scan analysis

Get your FREE Immuno-Oncology Therapy Analysis by ta-Scan

Today brings the start of the Immuno-Oncology Summit 2017 in Boston, supporting researchers in developing the next generation of immunotherapies. Immuno-oncology researchers are changing the way we treat cancer by unleashing the immune system and achieving functional cures in some cancers.

MDCPartners and its ta-Scan team contribute to this purpose by teaching how clinical planners can leverage our clinical businesses intelligence software and our data merging services to get to their answers faster. The ta-Scan team created a useful analysis on oncolytic virus therapies in clinical trials. We thought today would be a good occasion to share this report with you.

>>> Click here to download the analysis <<<

Share on:
Tweet about this on TwitterShare on LinkedIn


  • Introduction to ta-Scan

    Get to know ta-Scan better with this general introduction fact sheet.

    US Letter Format | A4 Format
  • ta-Scan for Clinical Trial Planning & Site Selection

    Learn how to use ta-Scan for clinical trial planning and site selection in this fact sheet.

    US Letter Format | A4 Format
  • ta-Scan for Expert Profiling & Medical Affairs

    Learn how to use ta-Scan for expert profiling and medical affairs.

    US Letter Format | A4 Format
  • ta-Scan for Competitive Intelligence & Disease Landscapes

    Learn how to use ta-Scan for competitive intelligence and disease landscapes in this fact sheet.

    US Letter Format | A4 Format
  • ta-Scan's Trial Feasibility Wizard

    Find out more information about ta-Scan's Trial Feasibility Wizard in this fact sheet.

    US Letter Format | A4 Format

Connect with MDCPartners

Follow us on LinkedIn

Follow us on Twitter

Top of Page